Borrelia burgdorferi Antibody, IgM by Immunoblot
Do not order in the absence of a positive or equivocal first-tier screening test for Lyme disease.
Second-tier testing for use ≤4 weeks after symptom onset.
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
CSF or plasma. Contaminated, heat-inactivated, severely hemolyzed, severely lipemic, and severely icteric specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Effective August 15, 2011
For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, or 41 kDa. All other banding patterns are reported as negative.
Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent EIA test and confirm equivocal and positive with immunoblot. Both IgM and IgG immunoblots should be performed on specimens less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot should be performed on specimens greater than 4 weeks after disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate immunoblot testing within 10 days.
|Component Test Code*||Component Chart Name||LOINC|
|0050253||B. burgdorferi Antibody IgM Immunoblot||6321-4|
- Lyme Ab
- Lyme Antibodies Detection
- Lyme Antibodies IgM/IgG by Western Blot
- Lyme Disease
- Lyme Disease by PCR